UBS analysts have issued a sell recommendation on GE HealthCare shares, citing insufficient market concern over emerging competitive threats. In their January 2026 research note, the Swiss bank highlights two primary risk factors: intensifying competition from Chinese medical-equipment manufacturers, which have increased global market share by an estimated 8% over the past two years, and the looming threat of a low-cost generic rival to GE HealthCare’s core imaging consumables. UBS projects that if a generic producer captures just 10% of consumables volume within 18 months, GE HealthCare’s annual revenues—currently estimated at $19 billion—could face a downside of up to $1.5 billion. The firm warns that investors have largely dismissed these risks, leaving shares vulnerable to a downward revaluation once early competitive data emerge.

UBS forecasts continued upside for gold after bullion climbed approximately 7% in January, following a near 65% rally throughout 2025. In their latest quarterly precious-metals report, the bank points to a combination of prolonged global central-bank asset purchases—currently averaging $40 billion per month—and an elevated frequency of geopolitical flashpoints, which UBS quantifies as having increased by 25% year-on-year. The bank’s strategist team now pegs gold’s fair-value range at $2,150 to $2,300 per ounce over the next six months, driven by low real interest rates in major developed economies and persistent safe-haven demand from institutional allocators. UBS also highlights that central banks added a net 800 tonnes of gold in 2025, the highest annual increase since 1967.

In the latest Zacks Style Scores publication, UBS secured the highest possible ranking in the Value category, indicating strong appeal for value-oriented investors. The Swiss bank achieved top scores across Price-to-Book and Price-to-Earnings metrics relative to its global peer group, with a trailing price-to-book ratio of 0.7x and a forward P/E of 10.5x, both in the bottom quintile of large financial institutions. Zacks highlights UBS’s robust capital adequacy—Tier 1 common equity stood at 14.8% at the end of 2025—and its cost-income ratio, which declined to 66.2% last year, as key fundamentals supporting its value positioning. The Style Scores framework suggests that UBS shares may offer a potential total return of 12% over the next 12 months, based on historical mean reversion in valuation multiples.

In an interview with Swiss newspaper Tages-Anzeiger published this week, UBS Group CEO Sergio Ermotti reiterated his preference for appointing his successor from within the bank’s existing leadership ranks. Ermotti noted that internal candidates benefit from continuity in executing UBS’s global strategy, which has seen return on tangible equity rise from 13.5% in 2022 to 16.2% in 2025. He identified the Investment Bank and Wealth Management divisions—each contributing roughly 40% of group net profit last year—as critical talent pools for future leadership. Ermotti also confirmed that UBS’s board will begin a formal succession process in the second quarter of 2026, with the aim of ensuring a seamless handover ahead of his planned retirement in early 2027.